Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.

Current cancer drug targets - 1 Jan 2014

Shi Min, Shi Hailong, Ji Jun, Cai Qu, Chen Xuehua, Yu Yingyan, Liu Bingya, Zhu Zhenggang, Zhang Jun

Abstract excerpt

Mutation status of Kirsten rat sarcoma viral oncogene homolog (KRAS) may serve as a negative predictive marker of Cetuximab in treating colorectal cancer. The present study was to determine the role of KRAS status in EGFR antibody treatment for gastric cancer. KRAS status was clarified in SGC-7901 (wild type) and YCC-2 (G→A mutation) gastric cancer cell lines. Anti-proliferative and pro-apoptotic effects of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cetuximab
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Extracellular Signal-Regulated MAP Kinases

Share to Mice, Nude

Share to ras Proteins

Share to Stomach Neoplasms

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 24467518
DOI: 10.2174/1570163811666140127145031

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cetuximab inhibits gastric cancer growth in vivo, independent of KRAS status.PMID 24467518Read ↗

In vitro and in vivo antitumor activity of cetuximab in human gastric cancer cell lines in relation to epidermal growth factor receptor (EGFR) expression and mutational phenotype.Semantic proximity Read ↗

Targeting the PI3K signaling pathway in KRAS mutant colon cancer.Semantic proximity Read ↗

The efficacy of IGF-I receptor monoclonal antibody against human gastrointestinal carcinomas is independent of k-ras mutation status.Semantic proximity Read ↗

EGFR gene status predicts response and survival benefit in a preclinical gastric cancer trial treating patient‑derived xenografts with cetuximab.Semantic proximity Read ↗

A subset of gastric cancers with EGFR amplification and overexpression respond to cetuximab therapy.Semantic proximity Read ↗

Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines.Semantic proximity Read ↗

Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression.Semantic proximity Read ↗

The effect of forced expression of mutated K-RAS gene on gastrointestinal cancer cell lines and the IGF-1R targeting therapy.Semantic proximity Read ↗

Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines.Semantic proximity Read ↗

Dual silencing of EGFR and HER2 enhances the sensitivity of gastric cancer cells to gefitinibSemantic proximity Read ↗

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab.Semantic proximity Read ↗

EGFR, HER-2 and KRAS in canine gastric epithelial tumors: a potential human model?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.